. Author manuscript; available in PMC: 2011 Feb 1.

Published in final edited form as: Pediatr Clin North Am. 2010 Feb;57(1):1–25. doi: 10.1016/j.pcl.2009.11.005

Table 4.

Results of SCT as Post-Remission Therapy for Childhood AML in First Remission

Study Group	Disease Free Survival			Median Follow- Up	Reference
Study Group	Matched Related Donor SCT	Chemotherapy	Autologous SCT	Median Follow- Up	Reference
AML-80	43%	31%	-	6 years	Dahl 1990 [106]
AIEOP LAM-87	51%^*	27%	21%	5 years	Amadori 1993 [94]
CCG-213	54%^*	37%	-	5 years	Wells 1994 [108]
CCG-251	45%^*	32%	-	8 years	Nesbit 1994 [107]
POG-8821	52%^*	36%	38%	3 years	Ravindranath 1996 [93]
MRC AML-10	61%^*	46%	68%^ˆ	7 years	Stevens 1998 [87]
AML BFM-93	64%	61%	-	5 years	Creutzig 2001 [86]
CCG-2891	55%^*	47%	42%	8 years	Woods 2001 [95]
LAME-89/91	72%^*	48%	-	6 years	Perel 2002 [88] Aladjidi 2003 [109]

Key: * p≤0.05 allogeneic vs. others;

^ˆ

p≤0.05 autologous vs. chemotherapy